- 1939
- 1942
- 1949
- 1963
- 1964
- 1975
- 1980-1989
- 1986
- 1991
- 1998
- 2001
- 2002
- 2003
- 2005
- 2006
- 2007
- 2009
- 2012 - 2015
- 2015
- 2015
-
Zeltia is founded
Zeltia is stablished to serve a territory that is lacking access to medicines, using local medicinal plants and animal subproducts as a source of inspiration. -
In search of natural products
featureFrom the beginning, Dr. Fernando Servet and his colleagues are able to produce numerous drugs, including slow-release insulins, sulfonamids, alkaloids from ergot fungi, ephedrine and other molecules to treat heart and metabolic diseases, and gynecological disorders. -
ANTIBIOTICOS is born
magnis disAlong with other cutting-edge laboratories, Zeltia participates in the creation of the start-up of Antibióticos S.A. -
-
A growing company
$750 million firstUnder Zeltia's management, three new companies are born to serve three different markets: the agrarian industry (Zeltia Agraria), the pharmaceutical industry (ICI Farma), and chemical and animal drug products (Cooper Zeltia). -
Boosting the chemical sector
sit ametAfter a partnership with the German company Desowag Bayer Holzschultz, a new company called Xylazel is launched, that develops products for protecting and treating wood and metal. -
Focusing in R&D
registersZeltia focused its investment a R&D efforts on the companies fully-owned by the Group and removes Antibióticos S.A. and ICI Farma from its business strategy. -
PHARMAMAR IS FOUNDED
releasesA crucial year for Zeltia, as PharmaMar, a pioneering enterprise envisioned to bring marine-inspired innovative drugs to the oncology arena is founded by José María Fernández Sousa-Faro -
New areas of research
The early Cooper Zeltia came to an end and Zelnova remains as the chemical Company. This same year the group enters the molecular and genetic testing area, creating Pharma Gen, a company commited to the development of molecular diagnostics and forensic genetic-based analysis. -
-
Elucidation of trabectedin
The PharmaMar R&D team finishes the chemical synthesis process to obtain its first marine-derived anti-cancer drug, YONDELIS®, by means of of chemical semi-synthesis. -
Our molecular diagnostics
Pharma Gen rebrands its name and logo to GENOMICA, a company that is becoming a leader in the field of molecular diagnostics in Spain. -
Pharmamar headquarters
PharmaMar establishes its headquarters in Colmenar Viejo outside Madrid to expand the R&D department and the production plant. -
Research in ovarian cancer
PharmaMar begins the phase III study in ovarian cancer using the synthetic version of its first marine-derived anticancer drug in humans for the first time. -
Sylentis is born
In order to strengthen the Company in the biotecnological space, a spin-off called Sylentis is created to address unmet medical needs using a gene silencing platform to develope innovative drugs. -
Yondelis® approved in Europe
PharmaMar gets the approval of the European Commission to market the first anticancer drug of marine origin, YONDELIS®, in soft tissue sarcoma which marks the first approval of a Spanish drug through a centralized procedure. -
Second indication for Yondelis®
PharmaMar obtiens a second indication for YONDELIS® in ovarian cancer, ang the FDA approves the manufacturing process of the active ingredients, opening the door to the US oncology market. -
PharmaMar’s global expansion
PharmaMar continues its global expansion and open four affiliates over the course of three years in Italy, Germany, France and the UK. -
YONDELIS® enters the US and Japanese market
Yondelis® is approved in the US and Japan for soft tissue sarcoma, a milestone for a Spanish anticancer drug. -
Reverse merger between Zeltia and PharmaMar
At the end of 2015 a corporate restructuring leads to the reverse merger of PharmaMar and Zeltia, focusing the company on oncology, with PharmaMar now as the Holding Co. of the innovative business units.
Board of Directors
The Board of Directors of PharmaMar is chaired by José María Fernández Sousa-Faro and is responsible for deciding on the most important issues for the company, including those related to governance.
Other Businesses
PharmaMar’s core business is oncology and it fully owns other companies that cover different aspects of healthcare and consumer chemical products.
Awards and Recognition
PhamaMar´s has been awarded and recognized by several institutions and agencies because of its commitment to discovering new marine-derived compounds, to society, to biodiversity, and to its people.
